Journal of Acute Care

Register      Login

VOLUME 3 , ISSUE 2 ( May-August, 2024 ) > List of Articles

Original Article

Patterns of Acute Kidney Injury and Vasopressor Effects in Septic Patients with Poor Cardiac Function

Gunchan Paul, Sravani V Mandava, Parshotam L Gautam, Aarti Mona

Keywords : Acute kidney injury, Dobutamine, Renal resistive index, Sepsis, Stages of acute kidney injury

Citation Information : Paul G, Mandava SV, Gautam PL, Mona A. Patterns of Acute Kidney Injury and Vasopressor Effects in Septic Patients with Poor Cardiac Function. 2024; 3 (2):65-71.

DOI: 10.5005/jp-journals-10089-0125

License: CC BY-NC 4.0

Published Online: 19-08-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: Sepsis is a life-threatening organ dysfunction, and acute kidney injury (AKI) is one of the most common complications of sepsis, as well as a cause of high mortality. This study aimed to determine the differences in the incidence of AKI, renal perfusion, clinical course, and outcome of septic patients with preserved or poor ejection admitted to the intensive care unit (ICU) of a tertiary care hospital. Materials and methods: This prospective, observational study included all consecutive patients admitted with septic shock to the ICU from March 2020 to November 2021. Index echocardiography was done within the first 6 hours of admission to the ICU. The vital hemodynamic parameters, dose of vasopressors, serum lactate, urine output, central venous pressure (CVP), and renal resistive index (RRI) were monitored at admission and 1, 6, 12, 24, and 48 hours following the start of vasopressors, with 0 hour being the time for initiation of vasopressors. Serum creatinine and sequential organ failure assessment (SOFA) scores were measured every day for 72 hours. Results: Among 50 adult patients, there were 17 patients with ejection fraction (EF) <40% (group I) and 33 patients with EF ≥40% (group II). The heart rate and CVP were higher in group I at baseline and at the start of vasopressor following fluid resuscitation. There was a significant difference in CVP between the groups at 0 hours, with mean CVP being higher in group I and this difference persisted for a few hours after the start of vasopressors (p = 0.02 at 1 hour and p = 0.2, nonsignificant at 6 hours). The difference in 28-day mortality was not significant between the groups (p = 0.62). The incidence of AKI between the two groups was 47% (eight patients) and 79% (26 patients), respectively, and the difference was statistically significant (p = 0.001). Around 35% of patients in group I had stage 3 AKI (six patients among eight); however, in group II, only 9% (three patients) were in stage 3 AKI. The higher incidence of AKI in group II was mainly contributed to patients in stages 1 and 2 of AKI. However, serum lactate was significantly higher in group II at 0 hours, and this difference persisted for 6 hours. While renal perfusion parameter, RRI, and urine output were comparable between the groups at 0 hours but showed decreasing trends earlier in group I. There was a significant decrease (p = 0.046) in RRI accompanied by an increase in urine output (p = 0.006) in group I patients with septic shock following initiation of dobutamine. Conclusion: Sepsis is associated with high mortality, but AKI in septic patients was not dependent on the cardiac status of the patient. The patients with preserved EF received vasopressors to achieve hemodynamic stability. Hence, we conclude that the early choice and dose of vasopressors might have a beneficial effect on renal perfusion and reduce the incidence of stage III AKI.


PDF Share
  1. Lee SM, An WS. New clinical criteria for septic shock: serum lactate level as new emerging vital sign. J Thorac Dis 2016;8(7):1388–1390. DOI: 10.21037/jtd.2016.05.55
  2. Sturgess DJ, Marwick TH, Joyce C, et al. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit Care 2010;14(2):R44. DOI: 10.1186/cc8931
  3. Antonucci E, Fiaccadori E, Donadello K, et al. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care 2014;29(4):500–511. DOI: 10.1016/j.jcrc.2014.03.028
  4. Narvaez I, Canabal A, Martín C, et al. Incidence and evolution of sepsis-induced cardiomyopathy in a cohort of patients with sepsis and septic shock. Med Intensiva (Engl Ed) 2018;42(5):283–291. DOI: 10.1016/j.medin.2017.08.008
  5. L'Heureux M, Sternberg M, Brath L, et al. Sepsis-induced cardiomyopathy: a comprehensive review. Curr Cardiol Rep 2020;22(5):35. DOI: 10.1007/s11886-020-01277-2
  6. Chen H, Busse LW. Novel therapies for acute kidney injury. Kidney Int Rep 2017;2(5):785–799. DOI: 10.1016/j.ekir.2017.06.020
  7. Zarbock A, Nadim MK, Pickkers P, et al. Sepsis-associated acute kidney injury: consensus report of the 28th acute disease quality initiative workgroup. Nat Rev Nephrol 2023;19(6):401–417. DOI: 10.1038/s41581-023-00683-3
  8. Peerapornratana S, Manrique-Caballero CL, Gómez H, et al. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 2019;96(5):1083–1099. DOI: 10.1016/j.kint.2019.05.026
  9. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287
  10. Lin CY, Chen YC. Acute kidney injury classification: AKIN and RIFLE criteria in critical patients. World J Crit Care Med 2012;1(2):40–45. DOI: 10.5492/wjccm.v1.i2.40
  11. Dombrovskiy VY, Martin AA, Sunderram J, et al. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35(5):1244–1250. DOI: 10.1097/01.CCM.0000261890.41311.E9
  12. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets–an updated view. Mediators Inflamm 2013;2013:165974. DOI: 10.1155/2013/165974
  13. Alberti C, Brun-Buisson C, Chevret S, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Resp Crit Care Med 2005;171(5):461–468. DOI: 10.1164/rccm.200403-324OC
  14. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol 2017;14(1):30–38. DOI: 10.1038/nrcardio.2016.163
  15. Mulder BA, Damman K, Van Veldhuisen DJ, et al. Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis. Clin Cardiol 2017;40(9):740–745. DOI: 10.1002/clc.22725
  16. Marik P, Bellomo R. A rational approach to fluid therapy in sepsis. Br J Anaesth 2016;116(3):339–349. DOI: 10.1093/bja/aev349
  17. Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 2010;39(3):450–455. DOI: 10.1097/CCM.0b013e3181ffe0eb
  18. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370(9588):676–684. DOI: 10.1016/S0140-6736(07)61344-0
  19. Mahmoud KM, Ammar AS. Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock. Indian J Crit Care Med 2012;16(2):75–80. DOI: 10.4103/0972-5229.99110
  20. Stephane D, Gaelle C, Jean XM, et al. Renal arterial resistance in septic shock: effects of increasing mean arterial pressure with norepinephrine on the renal resistive index assessed with Doppler ultrasonography. Intens Care Med 2007;33(9):1557–1562. DOI: 10.1007/s00134-007-0665-4
  21. Sarraf M, Schrier RW. Cardiorenal syndrome in acute heart failure syndromes. Int J Nephrol 2011:2011:293938. DOI: 10.4061/2011/293938
  22. Al-Hesayen A, Parker JD. The effects of dobutamine on renal sympathetic activity in human heart failure. J Cardiovasc Pharmacol 2008;51(5):434–436. DOI: 10.1097/FJC.0b013e3181684026
  23. Zima E, Farmakis D, Pollesello P, et al. Differential effects of inotropes and inodilators on renal function in acute cardiac care. Eur Heart J Suppl 2020;22(Suppl D):D12–D19. DOI: 10.1093/eurheartj/suaa091
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.